Redeye: BioArctic - A bit stronger Q4 than expected, BMS deal a validation of BT technology
Redeye return with a research update following BioArctic's Q4 report and recent events, including the significant BMS deal and EU process, which overall leads to a slightly raised valuation.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/